What to know before choosing care for a sore joint

Sources

1. A randomized controlled study of 111 patients aged 18-65 with hip osteoarthritis compared three weekly ultrasound-guided injections of PRP, hyaluronic acid, or both. PRP had the lowest VAS at every follow-up and beat HA significantly at 6 months (mean VAS 21 vs 44). But the WOMAC advantage present at 2 and 6 months was NO LONGER significant at 12 months, and the combination arm did worse than PRP alone.

   Dallari D, et al. — Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study.. The American journal of sports medicine, 2016. DOI: 10.1177/0363546515620383.

2. The PRIMA trial randomized 100 patients with ankle osteoarthritis to two ultrasound-guided intra-articular PRP injections or saline placebo. AOFAS scores improved 10 points with PRP (63 to 73) and 11 points with placebo (64 to 75); the adjusted between-group difference over 26 weeks was -1 (95% CI -6 to 3, p=0.56). The authors state the results do not support using PRP for ankle osteoarthritis. The evidence for a biologic in one joint does not transfer to another.

   Paget LDA, et al. — Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.16602.

3. A systematic review and meta-analysis of randomized trials found that augmenting arthroscopic rotator cuff repair with platelet-rich plasma reduces the retear rate and improves clinical function scores, whereas platelet-rich FIBRIN gives no clinically meaningful benefit - with the authors cautioning about the small number and heterogeneity of studies. The shoulder's best biologic evidence is for PRP used ALONGSIDE a repair operation, not as a substitute for one.

   Peng Y, et al. — Efficacy of platelet-rich plasma and platelet-rich fibrin in arthroscopic rotator cuff repair: A systematic review and meta-analysis.. PM & R : the journal of injury, function, and rehabilitation, 2023. DOI: 10.1002/pmrj.13049.

4. A pairwise and network meta-analysis of 18 randomized trials in rotator cuff TENDINOPATHY found corticosteroid helps at 3-6 weeks but not beyond 24 weeks, while PRP and prolotherapy may yield better outcomes in the long term (over 24 weeks) - with the authors warning that heterogeneity requires cautious interpretation. Tendon and joint-surface problems do not behave the same way, and a shoulder page should not borrow knee-OA evidence.

   Lin MT, et al. — Comparative Effectiveness of Injection Therapies in Rotator Cuff Tendinopathy: A Systematic Review, Pairwise and Network Meta-analysis of Randomized Controlled Trials.. Archives of physical medicine and rehabilitation, 2019. DOI: 10.1016/j.apmr.2018.06.028.

5. The evidence overview underpinning the 2020 EULAR recommendations on intra-articular therapies pooled 29 quality-appraised systematic reviews. Hyaluronic acid showed a small effect on pain and function in KNEE OA but not in hip OA or shoulder capsulitis; intra-articular glucocorticoid showed small effects in knee OA and on function in hip OA and shoulder capsulitis; PRP showed benefit in knee OA but NOT in hip OA, and mesenchymal stem cells behaved similarly. Overall conclusion: most intra-articular therapies exert SMALL effects and are well tolerated.

   Rodriguez-García SC, et al. — Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews.. RMD open, 2021. DOI: 10.1136/rmdopen-2021-001658.

6. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

7. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA and strongly recommends topical NSAIDs (Level 1A), while strongly recommending AGAINST oral and transdermal opioids (Level 5). The treatments with the strongest evidence in this condition remain the least dramatic ones.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

8. The Cochrane review of exercise for knee osteoarthritis found high-quality evidence that land-based therapeutic exercise provides short-term benefit in pain and physical function, sustained for at least 2-6 months after the programme ends, with mild transient soreness the only reported adverse effect across 45 trials. It is the best-evidenced treatment for this condition and it costs nothing per injection.

   Fransen M, et al. — Exercise for osteoarthritis of the knee.. The Cochrane database of systematic reviews, 2015. DOI: 10.1002/14651858.CD004376.pub3.

9. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

10. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

    Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.